OMGA - Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD's The Liver Meeting® 2023 | Benzinga
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that it will present new preclinical data demonstrating the potential of epigenomic controllers for the treatment of inflammatory and fibrotic liver diseases at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting® 2023, taking place in Boston, Massachusetts, November 10 – 14.
"Our OMEGA platform enables us to rationally and rapidly design epigenomic controllers to bidirectionally tune the expression of one or multiple genes pre-transcriptionally," said Mahesh Karande, President and Chief Executive Officer of Omega Therapeutics. "These preclinical data demonstrate the potential of programmable mRNA development candidates to controllably upregulate the expression of a single gene to drive liver regeneration in models of fibrosis, as well as the ability to simultaneously downregulate the expression of multiple genes linked to inflammatory liver diseases with a single epigenomic controller. Together, these findings underscore the versatile capabilities of our OMEGA platform and the potential of precision epigenomic control to address a broad range of diseases."
Details for the poster presentations are as follows:
Title: Targeting CXCL9/CXCL10/CXCL11 using novel epigenomic controllers for the treatment of inflammatory liver disease
Poster number: 2621-A
Date and Time: November 11, 2023, from 1:00 p.m. to 2:00 p.m. ET
This poster has been selected by AASLD as a "Poster of Distinction", having been classified as being in the top 5% of scored poster abstracts and will receive special recognition in the Poster Hall.
Title: Induction of Hepatocyte Nuclear Factor 4 alpha (HNF4?) using novel epigenomic controllers
Poster number: 3444-A
Date and Time: November 12, 2023, from 1:00 p.m. to 2:00 p.m. ET
The posters will be made available on the Omega website at https://omegatherapeutics.com/our-science/#publications-research at the same time as the presentations.
About the OMEGA Platform
The OMEGA platform leverages the Company's deep understanding of gene regulation, genomic architecture and epigenetic mechanisms to design programmable epigenomic mRNA medicines that precisely target ...